Markets

Insider Trading

Hedge Funds

Retirement

Opinion

12 Best Medical Device Stocks To Buy Now

In this piece, we will take a look at the twelve best medical device stocks to buy now. If you want to skip our introduction to the industry and jump to the top five stocks in this list, then take a look at 5 Best Medical Device Stocks To Buy Now.

The outset of the coronavirus pandemic and the rapid growth in manufacturing technology over the recent years has led to renewed investor interest and renewed fortunes for healthcare companies that have fresh funds and new technological avenues available to them for development.

This industry is divided into several sectors, one of which is the medical devices segment. To understand which companies make up the medical device industry, a definition by the Food and Drug Administration (FDA) is suitable, as it states that a medical device is any “instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory” that is used in relation to diseases.

Naturally, this covers a wide variety of objects, from simple ones such as syringes to more complicated ones such as heart stents. According to data from SelectUSA, there are more than 6,000 medical device companies in the United States, and the bulk of these are small to medium enterprises (SMEs). As far as the industry goes, several market research reports paint an optimistic picture and positive compounded annual growth rates (CAGRs) for the industry.

For instance, BCC Research estimates that the industry was worth $605 billion in 2020 and it will grow at a 5.6% CAGR to stand at $796 billion as 2025 comes to an end. Similarly, Fortune Business Insights believes that the market was worth $488 billion in 2021 and it will grow at a 5.5% CAGR to be worth $718 billion in 2029. Finally, Zion Market Research outlines that a small segment of the medical devices market, which deals primarily with smart devices such as those capable of connecting with each other and with the Internet, will be worth $48 billion by the end of 2028, growing at a CAGR of 10.9% and nearly doubling its value of $26 billion in 2021.

Therefore, the medical devices market is a strong subsegment of the broader healthcare industry, and in this list, we’ve identified some of the strongest companies in the industry. Out of these, some companies that are likely to cross your mind should include Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Medtronic plc (NYSE:MDT).

smart.art/Shutterstock.com

Our Methodology

In order to sift out some of the top medical device companies, we took a broader look at the industry to identify relevant trends. Then, the firms that can end up benefiting from these were identified. After this, they were ranked through hedge fund interest gathered through Insider Monkey’s survey of 912 funds for Q1 2022.

12 Best Medical Device Stocks To Buy Now

12. IRIDEX Corporation (NASDAQ:IRIX)

Number of Hedge Fund Holders: 3

IRIDEX Corporation (NASDAQ:IRIX) is an ophthalmic medical technology company that sells products such as laser systems, delivery devices, and other platforms to treat eye diseases. It is based in Mountain View, California, United States. IRIX ranks 12th in our list of best medical device stocks to buy now.

IRIDEX Corporation (NASDAQ:IRIX)’s strongest factor is the fact that it is developing a treatment for glaucoma. This eye disease currently has no treatment options, and IRIDEX Corporation (NASDAQ:IRIX)’s treatment involves inserting an implant into the eye which then automatically relieves pressure. Another laser-based glaucoma treatment from the company gained regulatory approval in China in June 2022.

Insider Monkey scanned 912 hedge fund portfolios for this year’s first quarter and discovered that 3 had held a stake in IRIDEX Corporation (NASDAQ:IRIX).

Out of these, Jim Simons’s Renaissance Technologies is IRIDEX Corporation (NASDAQ:IRIX)’s largest investor. It has a $2.5 million stake that comes through 546,812 million shares.

IRIDEX Corporation (NASDAQ:IRIX) joins Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), and Medtronic plc (NYSE:MDT) in the list of some of the top medical devices stocks out there.

11. Abiomed, Inc. (NASDAQ:ABMD)

Number of Hedge Fund Holders: 24

Abiomed, Inc. (NASDAQ:ABMD) is an American company headquartered in Danvers, Massachusetts that focuses on developing medical devices for the heart. These include heart and flow pumps, and the firm also offers other technological solutions such as a cloud platform.

Abiomed, Inc. (NASDAQ:ABMD) is a leader in its space and the company is on track to developing what will be the world’s smallest heart pump, measuring 3.5 millimeters in diameter. The firm is also developing an industry leading treatment for acute decompensated heart failure (ADHF), after acquiring another firm last year. Additionally, the global heart pump market has a 15% CAGR estimate up to 2027, making Abiomed, Inc. (NASDAQ:ABMD) a key player in a large market.

Insider Monkey’s Q1 2022 survey of 912 hedge funds revealed that 24 had bought the company’s shares.

Out of these, Jim Simons’s Renaissance Technologies is the company’s largest investor as it owns 1.4 million shares that are worth $468 million.

10. Penumbra, Inc. (NYSE:PEN)

Number of Hedge Fund Holders: 29

Penumbra, Inc. (NYSE:PEN) offers a host of medical devices such as thrombectomy systems, revascularization devices, and neurovascular embolization coiling systems. It is headquartered in Alameda, California, United States.

Penumbra, Inc. (NYSE:PEN) targets several valuable medical device markets such as that of coronary vessel occlusion. On this front, the company’s CAT Rx catheter showed impressive performance in a 2021 test that saw it post zero device related adverse events in patients and a blush grade of 3 (widely thought of as the standard for normal) in 100% of the patients.

RBC Capital set an Outperform rating and a $195 share price target for Penumbra, Inc. (NYSE:PEN) in July 2022, stating that the firm is a key player in an underdeveloped market with huge potential. Insider Monkey’s 912 hedge fund survey for this year’s first quarter outlined that 29 had held a stake in the company. PEN ranks 10th in our list of best medical device stocks to buy now.

Penumbra, Inc. (NYSE:PEN)’s largest investor is Ken Griffin’s Citadel Investment Group which owns 367,149 shares that are worth $81 million.

9. Stryker Corporation (NYSE:SYK)

Number of Hedge Fund Holders: 41

Stryker Corporation (NYSE:SYK) is an American company that develops several kinds of implants and surgical equipment. The implants target areas of the body such as the knee and the spine, while the surgical equipment offers surgeons a host of features. SYK ranks 9th in our list of best medical device stocks to buy now.

A strong point for Stryker Corporation (NYSE:SYK) is its dividend. The company currently pays out a $0.69 dividend per share per quarter for a 1.20% yield. Additionally, the company’s neurotechnology and spine segment’s growth of 12.64% is outpacing the sector CAGR of 7.9% and is expected to further benefit from the aging U.S. population – which is the company’s largest market as well.

Edward Jones raised the company’s share price rating to Buy in July 2022 as it stated that the firm is one of the fastest growing in its segment. Insider Monkey scanned 912 hedge fund portfolios for the first quarter of this year to discover that 41 had bought the company’s shares.

Stryker Corporation (NYSE:SYK)’s largest shareholder is Terry Smith’s  Fundsmith LLP which owns 5.8 million shares that are worth $1.5 billion.

8. Edwards Lifesciences Corporation (NYSE:EW)

Number of Hedge Fund Holders: 45

Edwards Lifesciences Corporation (NYSE:EW) is a medical devices company that manufactures products that cover the heart, critical care, and surgical monitoring. The firm is headquartered in Irvine, California, United States.

Edwards Lifesciences Corporation (NYSE:EW) is operating in a strongly growing market, whose total addressable market (TAM) is estimated to double from a current $10 billion to $20 billion in 2028. Out of these, the company’s primary earner, a heart replacement valve, which accounts for 65% of its revenue, is estimated to sit at $10 billion in 2028 from a current $5 billion. Indicating Edwards Lifesciences Corporation (NYSE:EW)’s strength, the firm captured $3.7 billion from this market as of its latest earnings.

Edwards Lifesciences Corporation (NYSE:EW)’s share price target was raised to $118 from $115 by Citi in July 2022, as it shared the belief that the stock can appreciate later this year. 45 of 912 hedge funds polled by Insider Monkey for this year’s March quarter had bought the company’s shares.

Edwards Lifesciences Corporation (NYSE:EW)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 7 million shares that are worth $836 million.

Harding Loevner mentioned the company in its Q4 2021 investor letter and outlined that:

“Innovation can foster growth in Health Care fields other than drug discovery. Edwards Lifesciences makes minimally invasive devices to treat heart disease or for critical care monitoring. Its transcatheter heart valve, SAPIEN, is the most-implanted aortic heart valve in the world. Having settled a lawsuit with Abbott over alleged patent infringement, Edwards is now moving ahead with a newer product line called PASCAL to treat elderly or frail patients—for whom currently available treatments are ineffective—for mitral and tricuspid disease. PASCAL is the fruit of the company’s ongoing investment in research and development. Between PASCAL and its next-generation SAPIEN valve, the company expects to double its addressable market to approximately US$20 billion by 2028.”

7. Align Technology, Inc. (NASDAQ:ALGN)

Number of Hedge Fund Holders: 45

Align Technology, Inc. (NASDAQ:ALGN) is a clear aligner and intraoral scanner manufacturer that serves the needs of orthodontists and dentists. It is headquartered in Tempe, Arizona, United States.

Align Technology, Inc. (NASDAQ:ALGN) estimates that out of the 21 million orthodontist cases globally in 2021, 19 million ended up using its products. The company also has more than 2,000 active and pending patents globally, lending it a key advantage in an industry with an estimated CAGR of 19.7%. Additionally, by the end of last year, Align Technology, Inc. (NASDAQ:ALGN) had trained more than 122,000 dentists with its tools, for a strong customer market.

Insider Monkey’s 912 hedge fund survey for the first quarter of this year revealed that 45 had invested in the company.

Align Technology, Inc. (NASDAQ:ALGN)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 571,043 shares that are worth $248 million.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…